Amarin Corp Plcuk (AMRN) Liabilities and Shareholders Equity (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Liabilities and Shareholders Equity of $645.8 million for Q1 2026, down 1.52% YoY from $655.7 million in Q1 2025, and down 3.73% sequentially from $670.8 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $645.8 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 1.52% year-over-year to $645.8 million; the TTM figure through Mar 2026 stood at $2.6 billion (down 8.48% YoY), while the FY2025 annual figure was $670.8 million, down 2.13% from the prior year.
- Liabilities and Shareholders Equity fell to $645.8 million in Q1 2026, from $670.8 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for AMRN reached as high as $973.7 million in Q1 2022 and fell as low as $645.8 million in Q1 2026.
- The 5-year median for Liabilities and Shareholders Equity is $799.9 million (2024), against an average of $791.8 million.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity dropped 17.6% — and 2026, when it retreated 1.52%.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $886.2 million in 2022, then decreased by 6.15% to $831.7 million in 2023, then retreated by 17.6% to $685.3 million in 2024, then decreased by 2.13% to $670.8 million in 2025, then retreated by 3.73% to $645.8 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $645.8 million, $670.8 million, and $659.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 116.58 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 200.89 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 136.46 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 114.02 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 128.69 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 92.50 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 56.28 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 208.00 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 645.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 645.76 Mn |
| Dec 31, 2025 | 670.78 Mn |
| Sep 30, 2025 | 659.81 Mn |
| Jun 30, 2025 | 670.13 Mn |
| Mar 31, 2025 | 655.70 Mn |
| Dec 31, 2024 | 685.35 Mn |
| Sep 30, 2024 | 750.62 Mn |
| Jun 30, 2024 | 799.90 Mn |
| Mar 31, 2024 | 790.01 Mn |
| Dec 31, 2023 | 831.68 Mn |
| Sep 30, 2023 | 839.03 Mn |
| Jun 30, 2023 | 860.02 Mn |
| Mar 31, 2023 | 860.19 Mn |
| Dec 31, 2022 | 886.18 Mn |
| Sep 30, 2022 | 908.30 Mn |
| Jun 30, 2022 | 973.24 Mn |
| Mar 31, 2022 | 973.71 Mn |
| Dec 31, 2021 | 1.07 Bn |
| Sep 30, 2021 | 1.04 Bn |
| Jun 30, 2021 | 1.04 Bn |